Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
EYPTthis companyEyePoint Pharmaceuticals, Inc.	$0.35	-5.76×	4.37×	42.66×	-5.49×	-1218.8%	93.4%	-776.0%	-739.4%	-75.8%	-74.0%	-18.2%	0.07×	0.34×	0×	8.88×	0.0%	2	-11.09	1	C-
BCAXBicara Therapeutics Inc. Common Stock	$9.38	-6.68×	2.29×	0×	-6×	-79.8%	0.0%	0.0%	0.0%	-34.4%	-38.6%	-11.6%	0×	0.69×	0×	14.58×	0.0%	1	5.84	2	C+
KODKodiak Sciences Inc.	$105.57	-6.47×	9.45×	0×	-7.06×	-99.2%	0.0%	0.0%	0.0%	-146.1%	-73.7%	-9.2%	1.01×	0.25×	0×	4.72×	0.0%	1	7.23	1	D+
KURAKura Oncology, Inc.	$7.56	-3.27×	5.23×	13.5×	-2.84×	72.0%	99.9%	-449.9%	-412.9%	-160.0%	-48.8%	-7.8%	0.12×	0.47×	-200.81×	6.06×	0.0%	3	-2.79	2	C
NRIXNurix Therapeutics, Inc.	$15.81	-5.54×	2.72×	17.45×	-5.2×	-213.0%	77.5%	-340.2%	-314.9%	-49.1%	-47.3%	-18.0%	0.1×	0.78×	0×	7.02×	0.0%	7	9.1	4	A-
PRMEPrime Medicine, Inc.	$4.32	-2.57×	4.27×	111.44×	-2.91×	-102.2%	-58.1%	-4498.1%	-4342.4%	-166.4%	-66.5%	-32.4%	0.96×	-0.27×	0×	4.84×	0.0%	2	-5.36	1	D+
Peer median	—	-5.54×	4.27×	13.5×	-5.2×	-99.2%	0.0%	-340.2%	-314.9%	-146.1%	-48.8%	-11.6%	0.12×	0.47×	0×	6.06×	0.0%	2	5.84	2	—